ProfileGDS5678 / 1432148_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 40% 40% 38% 40% 44% 39% 39% 40% 40% 40% 39% 39% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9501140
GSM967853U87-EV human glioblastoma xenograft - Control 22.9158440
GSM967854U87-EV human glioblastoma xenograft - Control 32.9153340
GSM967855U87-EV human glioblastoma xenograft - Control 42.8118838
GSM967856U87-EV human glioblastoma xenograft - Control 52.8569340
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1074844
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9459339
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8926139
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8884540
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9043440
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9004340
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.856339
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9079539
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9068540